Christopher Short

A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation

Jane C. Davies, Isabelle Sermet‐Gaudelus, Lutz Naehrlich et al. · Journal of Cystic Fibrosis · 2020 · 64 citations

Integrating the multiple breath washout test into international multicentre trials

Clare Saunders, Renée Jensen, Paul D. Robinson et al. · Journal of Cystic Fibrosis · 2019 · 62 citations

Asthma, Clinical Trials, International Health +3

Ivacaftor in People with Cystic Fibrosis and a <i>3849+10kb C</i> → <i>T</i> or <i>D1152H</i> Residual Function Mutation

Eitan Kerem, Malena Cohen‐Cymberknoh, Reuven Tsabari et al. · Annals of the American Thoracic Society · 2020 · 32 citations · Full text

Impact of cross-sensitivity error correction on representative nitrogen-based multiple breath washout data from clinical trials

Paul D. Robinson, Renée Jensen, Ryan A. Seeto et al. · Journal of Cystic Fibrosis · 2021 · 23 citations

Asthma, Clinical Trials, Lung Mechanics +5

Abnormal pro-gly-pro pathway and airway neutrophilia in pediatric cystic fibrosis

A R Turnbull, Chloe J. Pyle, Dhiren F. Patel et al. · Journal of Cystic Fibrosis · 2019 · 21 citations · Full text